Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Feb 15, 2022; 14(2): 434-449
Published online Feb 15, 2022. doi: 10.4251/wjgo.v14.i2.434
Published online Feb 15, 2022. doi: 10.4251/wjgo.v14.i2.434
Figure 1 Kaplan-Meier analysis of overall survival in patients with limited metastatic disease (arm B) who underwent surgery and no surgery.
(Adapted from Al-Batran et al[25] with permission from the American Medical Association. Citation: Al-Batran SE, Homann N, Pauligk C. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. JAMA Oncol 2017; 3: 1237-1244. Copyright © American Medical Association.
Figure 2 Diagram of the FLOT-5 RENAISSANCE Trial comparing chemotherapy alone vs surgical resection for oligometastatic gastric cancer.
FLOT: Fluorouracil, leucovorin, oxaliplatin and docetaxel.
Figure 3 Diagram for the actual therapeutic strategy for patients with oligometastatic gastric cancer.
HIPEC: Hyperthermic intraperitoneal chemotherapy.
- Citation: Chevallay M, Wassmer CH, Iranmanesh P, Jung MK, Mönig SP. Multimodal treatment in oligometastatic gastric cancer. World J Gastrointest Oncol 2022; 14(2): 434-449
- URL: https://www.wjgnet.com/1948-5204/full/v14/i2/434.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i2.434